We have presented a case whose migrated L4-S1 femur graft led to perforation of the cecum. We recommend that frequent radiologic follow-up should be done in patients at risk to show complications early enough to avert severe consequences.

One of the side effects of vaccines used to end the COVID-19 epidemic is non-specifically enlarged axillary lymph nodes. Such lymphadenopathy detected during clinical examination of breast cancer patients may require additional imaging or interventional procedures that should not normally be performed. This study has been designed to estimate the incidence of palpable enlarged axillary lymph node in breast cancer patients who had received COVID-19 vaccination in the past 3 months in the same arm as compared to those without vaccination. Breast cancer patients admitted to M.U. Medical Faculty Breast polyclinic between January 2021 and March 2022 were screened, and clinical staging was performed after thorough clinical examination. Among these patients with suspected enlarged axillary lymph node and those undergoing sentinel lymph node biopsy (SLNB), they were divided into two groups as vaccinated and unvaccinated. Age, menopausal status, tumor size, tumor location, surgery, pathology results, hormonal receptor status, and SLNB results were statistically compared with groups. There was no significant difference between groups in terms of age, menopause, tumor size, tumor location, surgery, pathological results, and hormone receptor status. The SLNB being reported as reactive only was 89.1% in the vaccinated group and 73.2% in the non-vaccinated group which was statistically significant different. Reactive lymph nodes were commonly found with an excess of 16% in patients who had received COVID-19 vaccination in the past 3 months. This required caution and additional examination of the axillary lymph nodes in this period.

Background Any papillary lesion in the breast presents a diagnostic and therapeutic challenge. Encapsulated papillary carcinoma (ECP) is one of the rare types of breast cancer. Evidence-based guidelines are sparse. For this reason, there is no complete clarity in the diagnosis and treatment management, and there are not enough studies in the literature. This study aims to examine the necessity of sentinel lymph node sampling in the management of ECP in line with the patients' clinicopathological data. Methods We retrospectively screened with EPC in our clinic between January 2012 and March 2022. We recorded and statistically evaluated the patients' demographic, clinical, radiological, pathological, and treatment management. Results Sixty four EPC patients were identified. The final pathologic evaluation revealed that 19 patients (18.7%) had pure EPC, 27 patients (43.7%) had EPC with associated DCIS, and 18 patients (37.5%) had EPC associated with invasion. The mean age was 61, and 2 patients were male. Breast-conserving surgery was performed in 62 patients, and simple mastectomy was performed in 2. SLNB was found to be positive in only 1 of the patients. Sixty-three patients with EPC were hormone receptor-positive, one patient was triple negative, and they were associated with invasion. No death was in any patient; one had local recurrence, and a mastectomy was performed. Conclusions The overall prognosis and long-term survival of EPC is excellent. Our study and current literature indicate routine SLNB is overtreatment since surgical excision with negative margins is sufficient in EPC cases, and lymph node metastasis is rare, even with an invasive component.